Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines

被引:0
|
作者
Hideaki Tanami
Issei Imoto
Akira Hirasawa
Yasuhiro Yuki
Itaru Sonoda
Jun Inoue
Kohichiro Yasui
Akiko Misawa-Furihata
Yutaka Kawakami
Johji Inazawa
机构
[1] Medical Research Institute,Department of Molecular Cytogenetics
[2] Tokyo Medical and Dental University,Division of Cellular Signaling
[3] Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation,undefined
[4] Institute for Advanced Medical Research,undefined
[5] Keio University,undefined
[6] School of Medicine,undefined
来源
Oncogene | 2004年 / 23卷
关键词
malignant melanoma; mutation; gene amplification; comparative genomic hybridization;
D O I
暂无
中图分类号
学科分类号
摘要
Comparative genomic hybridization (CGH) using 40 cell lines derived from malignant melanomas (MMs) revealed frequent amplification at 7q33–q34 containing BRAF gene, which often is mutated in MM. We found this gene to be amplified to a remarkable degree in the MM cell lines that exhibited high-level gains at 7q33–q34 in CGH. Among 40 cell lines, the eight lines that revealed neither BRAF nor NRAS mutations showed even higher levels of BRAF mRNA expression than the 32 mutated lines, although DNA amplification at 7q33–q34 was not detected in every lines overexpressing BRAF. MM cells that carried wild-type BRAF and NRAS showed constitutive overexpression of B-Raf protein and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), even after serum starvation. Not only downregulation of the endogenously overexpressed wild-type B-Raf by antisense oligonucleotide but also a treatment with an inhibitor of mitogen-activated protein kinase kinase (MAPKK, MEK) reduced phosphorylated ERK1/2 and cell growth, whereas the exogenously expressed wild-type B-Raf promoted cell growth in MM cells. Our results provide the evidence that overexpression of wild-type B-Raf, in part but not always as a result of gene amplification, is one of the mechanisms underlying constitutive activation of the MAPK pathway that stimulates growth of MM cells.
引用
收藏
页码:8796 / 8804
页数:8
相关论文
共 50 条
  • [41] KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
    Maio, Michele
    Carlino, Matteo S.
    Joshua, Anthony M.
    McWhirter, Elaine
    Ribas, Antoni
    Ascierto, Paolo A.
    Miller, Wilson H., Jr.
    Butler, Marcus O.
    Ferrucci, Pier Francesco
    Zielinski, Robert R.
    Del Vecchio, Michele
    Gasal, Eduard
    Ghori, Razi
    Diede, Scott J.
    Croydon, Elizabeth
    Hamid, Omid
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 1 - 11
  • [42] Transduction of a wild-type p53 gene into human malignant melanoma cells
    Hakim, AA
    CANCER GENE THERAPY, 2001, 8 : S8 - S8
  • [43] Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
    Francisco Meraz-Torres
    Heike Niessner
    Sarah Plöger
    Simon Riel
    Barbara Schörg
    Nicolas Casadei
    Manfred Kneilling
    Martin Schaller
    Lukas Flatz
    Boris Macek
    Thomas Eigentler
    Olaf Rieß
    Claus Garbe
    Teresa Amaral
    Tobias Sinnberg
    Journal of Experimental & Clinical Cancer Research, 43
  • [44] Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
    P Dietrich
    S Kuphal
    T Spruss
    C Hellerbrand
    A K Bosserhoff
    Oncogene, 2018, 37 : 897 - 911
  • [45] Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis
    Tarhini, Ahmad
    Benedict, Agnes
    McDermott, David
    Rao, Sumati
    Ambavane, Apoorva
    Gupte-Singh, Komal
    Sabater, Javier
    Ritchings, Corey
    Aponte-Ribero, Valerie
    Regan, Meredith M.
    Atkins, Michael
    IMMUNOTHERAPY, 2018, 10 (14) : 1241 - 1252
  • [46] Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma
    Algazi, Alain Patrick
    Muthukumar, Adele H.
    O'Brien, Kelly
    Lencioni, Alex
    Tsai, Katy K.
    Kadafour, Maha
    Chapman, Paul B.
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma
    O'Day, Steven
    Gonzalez, Rene
    Kim, Kevin
    Chmielowski, Bartosz
    Kefford, Richard
    Long, Georgina
    Loquai, Carmen
    Cowey, Charles Lance
    Hauschild, Axel
    Hainsworth, John D.
    Hersey, Peter
    Boyle, Frances
    Evans, T. R. Jeffry
    Hamid, Omid
    Meneses, Nicole
    Andresen, Corina
    Ren, Min
    O'Brien, James P.
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
    Dietrich, P.
    Kuphal, S.
    Spruss, T.
    Hellerbrand, C.
    Bosserhoff, A. K.
    ONCOGENE, 2018, 37 (07) : 897 - 911
  • [49] ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
    Capparelli, Claudia
    Purwin, Timothy J.
    Heilman, Shea A.
    Chervoneva, Inna
    McCue, Peter A.
    Berger, Adam C.
    Davies, Michael A.
    Gershenwald, Jeffrey E.
    Krepler, Clemens
    Aplin, Andrew E.
    CANCER RESEARCH, 2018, 78 (19) : 5680 - 5693
  • [50] Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
    Meraz-Torres, Francisco
    Niessner, Heike
    Ploeger, Sarah
    Riel, Simon
    Schoerg, Barbara
    Casadei, Nicolas
    Kneilling, Manfred
    Schaller, Martin
    Flatz, Lukas
    Macek, Boris
    Eigentler, Thomas
    Riess, Olaf
    Garbe, Claus
    Amaral, Teresa
    Sinnberg, Tobias
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)